PRCT
HealthcarePROCEPT BioRobotics Corporation · Medical - Devices · $2B
What is PROCEPT BioRobotics Corporation?
PROCEPT BioRobotics is a surgical robotics company focused on urology, developing minimally invasive robotic systems to treat benign prostatic hyperplasia (BPH) in men.
The company develops, manufactures, and sells the AquaBeam Robotic System — an image-guided robotic platform used in urologic surgery. Revenue is generated through system placements at hospitals and clinics, along with recurring disposable and service revenue tied to Aquablation therapy procedures.
PROCEPT BioRobotics was incorporated in 2007 and is headquartered in Redwood City, California.
- AquaBeam Robotic System
- Aquablation therapy for BPH
- Image-guided minimally invasive urologic surgery
Is PRCT a Good Stock to Buy?
UQS Score rates PRCT as Below Average overall.
Growth stands out as the clearest bright spot in PRCT's profile, reflecting the rapid expansion of Aquablation therapy adoption. Risk is rated Neutral, suggesting the company does not carry outsized near-term financial danger relative to peers.
Quality and Moat are both rated Weak, pointing to limited profitability durability and a competitive position that has yet to solidify. Valuation is Elevated, meaning the market is pricing in significant future success.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PRCT pay dividends?
No — PROCEPT BioRobotics Corporation does not currently pay a dividend.
PRCT does not pay a dividend. As a growth-stage medical robotics company, capital is reinvested into expanding its install base, clinical evidence, and commercial infrastructure rather than returned to shareholders as income.
When does PRCT report earnings?
PROCEPT BioRobotics reports earnings on a quarterly cadence, typical for US-listed equities.
The company has been scaling its AquaBeam install base and procedure volumes, which drives both system and recurring revenue. Growth trends have been a key focus for investors tracking commercial momentum in the BPH robotics space.
For the most recent quarter's results, visit PROCEPT BioRobotics' investor relations page directly.
PRCT Price History
-35.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in PROCEPT BioRobotics Corporation?
Based on PROCEPT BioRobotics Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does PROCEPT BioRobotics do?
PROCEPT BioRobotics develops the AquaBeam Robotic System, an image-guided surgical robot used to treat benign prostatic hyperplasia (BPH) in men. The company sells systems to hospitals and generates recurring revenue through Aquablation therapy procedures.
Does PRCT pay dividends?
No, PRCT does not pay a dividend. The company is in a growth phase and reinvests available capital into commercial expansion and technology development rather than distributing income to shareholders.
When does PRCT report earnings?
PROCEPT BioRobotics reports on a standard quarterly schedule. For confirmed dates and the latest results, check the investor relations section of the company's official website.
Is PRCT a good stock to buy?
UQS Score rates PRCT as Below Average. Growth is rated Strong, but Quality and Moat are Weak, and Valuation is Elevated. Whether that profile fits your investment approach depends on your risk tolerance and time horizon.
Is PRCT overvalued?
PRCT carries an Elevated Valuation rating in the UQS framework, meaning the current price reflects high expectations for future growth. Investors should weigh that against the Weak Quality and Moat ratings before drawing conclusions.
What is PRCT's market cap bracket?
PRCT is classified as a small-cap stock, placing it in a segment that often carries higher volatility and liquidity risk compared to large- or mega-cap peers in the healthcare and medical device space.
Is PRCT a long-term quality investment?
From a long-term quality perspective, PRCT's Weak Quality and Moat ratings suggest the business has not yet established durable profitability or a strongly defensible competitive position. The Strong Growth rating indicates commercial traction, but long-term quality remains a work in progress.
What sector does PRCT belong to?
PRCT operates in the Healthcare sector, specifically within surgical robotics and medical devices, targeting the urology market with a focus on minimally invasive treatment of BPH.
Unlock Full PRCT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data
- ✓Compare PRCT against sector peers on a standardized scoring framework
- ✓Get the complete analyst view available to Pro members
Pro Analysis
PRCT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 37.1 | 16.3 | 32.0 | 82.3 | 57.5 | 0.0 | +1.4 |
| Apr 2, 2026 | 35.7 | 16.3 | 32.0 | 82.3 | 47.7 | 0.0 | — |
PRCT — Pillar Breakdown
Quality
— 16.3/100 (25%)PROCEPT BioRobotics Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 82.3/100 (20%)PROCEPT BioRobotics Corporation is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 57.5/100 (15%)PROCEPT BioRobotics Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)PROCEPT BioRobotics Corporation appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 32/100 (25%)PROCEPT BioRobotics Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PRCT.
Score Composition
Financial Data
More Stock Analysis
How is the PRCT UQS Score Calculated?
The UQS (Unified Quality Score) for PROCEPT BioRobotics Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses PROCEPT BioRobotics Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether PROCEPT BioRobotics Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.